The Role of Hormonal and Dietary Factors in Pancreatic Carcinogenesis by Christopoulou, A. et al.
HPB Surgery, 1993, Vol. 6, pp. 141-150
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1993 Harwood Academic Publishers GmbH
Printed in the United States of America
REVIEW ARTICLE
THE ROLE OF HORMONAL AND DIETARY
FACTORS IN PANCREATIC CARCINOGENESIS
A. CHRISTOPOULOU1’2, F. BLANC2 and H. JOYEUX
a)Laboratory of Nutrition and Experimental Oncology, t2)Department of Internal
Medicine E, University of Montpellier, Medical School Montpellier, France
(Received 11 May 1992)
The pancreatic cancer continues to represent an important problem, as a cancer with extremely poor
prognosis.
To date more than 16 chemicals have been shown to induce pancreatic tumors, in animal models. The
tumors developed in rats are essentially of acinar type and those in hamsters mostly of ductal type.
Many studies proved the direct or indirect role of hormonal and dietary factors in pancreatic cancer.
The development of alternative treatments according to biological and biochemical steps of carcinoge-
nesis is available as adjuvant treatment.
We present herein an overview of current experimental and clinical results in order to understand the
evolution, histogenesis and biological behaviour of pancreatic cancer.
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1. INTRODUCTION
Adenocarcinoma of the pancreas continues to represent an important problem
worldwide. It is a disease with an extremely poor prognosis: fewer than 20% of
affected patients survive the first year, and only 3% are alive five years after the
diagnosis1.
Despite this grim outcome, considerable progress has been made in our under-
standing of the pathogenesis of this disease with the lowest five-year survival rate.
However, an overview of current experimental and clinical results does offer some
promise for the development of more effective drug combinations or combined
modality regimens for systemic and local therapy. We present herein the most
recent data about the experimental and clinical models of pancreatic carcinogenesis
and also some comments about the therapeutic approach to pancreatic cancer.
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2. MODELS OF EXPERIMENTAL CARCINOGENESIS IN PANCREATIC
CANCER
The malignant tumors of the pancreas in humans are adenocarcinomas from
pancreatic ductal cells in 3/4 of the cases. All the other pancreatic cells participate
to a more or less important extent in pancreatic carcinogenesis2’3. It’s well known
that the pancreatic tissue contains fewer ductal cells than acinar cells. This means
that it is possible that pancreatic cancer is produced by a late cellular transforma-
tion of acinar to ductal cells3. Different models of pancreatic carcinogenesis were
developed in vivo and in vitro, in order to evaluate the different steps of pancreatic
carcinogenesis and the biological processes of the different pancreatic cells during
this differentiation3. In experimental models under the influence of different
carcinogens there is a transformation of acinar cells to ductal cell3.
In order to understand the evolution, histogenesis and biological behaviour of
exocrine pancreatic carcinoma, some reproducible experimental models have been
developed in certain rodent species. To date more than 16 chemicals have been
shown to induce pancreatic tumors. Although some of these chemicals appear
species specific in their effect on the pancreas, others have been shown to be
capable of inducing pancreatic tumors in more than one species4.
Pancreatic tumors can be induced experimentally in animals by lifelong administ-
ration of tobacco-specific nitrosamines in drinking water, as well as by parenteral
administration of other N-nitroso compounds, such as the N-nitrosobis (2-
hydroxypropyl) amine (BPH) and the N-nitroso (2-hydroxypropyl)-2-oxoptopyl
amine (HPOP) which are the most potent carcinogens in rat and hamster animal
models13. It has been suggested that these N-nitroso compounds reach the pancreas
either through the blood or through refluxed bile that is in contact with the
pancreatic duct1. These nitrosamines can be administrated by an only intra-venous
injection or repeated injections3.
The delay before the cancer is apparent after the introduction of the carcinogen
may vary from one month for the focal histologic lesions, to 4-6 months for lesions
> 3mm and finally plus to 1 year for the invasive pancreatic tumor2.
2.1 Carcinogenesis in Rat Models
The most used compound is the o-diazoacetyl-N serine (azaserine). Injecting as an
only dose intraperitoneously (IP) in rats produces DNA alterations during the first
hour and these alterations persist for 4 weeks and the DNA repair is completed
after 9 weeks. In vitro doses of 30/g/ml, produce DNA alterations in cellular
pancreatic lines2.
The principal target of azaserine is the acinar cell and the mode of action is the
alkylation of DNA. Therefore it is evident that the most frequent histologic
pancreatic lesions are nodular acinar cell atypia. These results suggest that the
acinar cell, in these models, is the exclusive cell of pancreatic cancer
differentiation2.
The different types of azaserine administration may play an important role in the
final result5’8. It has been proved that azaserine may play an initiator and/or a
promoter role. The incidence of pancreatic carcinomas varying with the total dose7.
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focal acinar cell atypias (diametre < lmm)
nodular acinar cell atypias (diametre > lmm and < 3mm)
adenomas (diametre > 3mm)
in situ carcinoma
adenocarcinoma with adipose tissue invasion.
The 7-12-dimethylbenz-(a)anthracene (DMBA) plays a role in the induction of
poorly differentiated pancreatic cancer3. The 4-hydroxyaminoquinolone-l-oxyde
(HAQO) by a single intravenous injection produces pancreatic necrosis in 48 hours
with regeneration in 72 hours and we observed most frequently tumors with atypia
or adenomas rather than cancers2.
Nd (N-methyl-N-nitroso-N-carbonyl)-L-ornithine (MNCO) acts directly. It pro-
duces nodular acinar cell atypia with pseudoductal structures only occasionally. On
the other hand the main disadvantage of this compound is the induction of cancer in
other organs3.
In conclusion pancreatic cancer in the rat animal model is an acinar cell type
carcinoma with different zones of cellular atypia3.
2.2 Carcinogenesis in Hamster Models
In hamsters, the nitrosamines induce a ductal type pancreatic carcinoma4. The most
commonly used are POP, its derivative, HPOP, and N-nitroso-2-6-dimethyl-
morpholine (NOMM) that can methylate pancreatic DNA at the level of guanin
and phosphate groups. The first lesions induced are hypertrophy or metaplasia of
ductal epithelium. Then papillary structures, similar to those observed in humans
appear. MNCO induces focal acinar atypia and further differentiation of the acinar
structures to ductal3.
The cellular origin of the cancers observed in hamsters is probably centro-acinar
and ductal with a secondary infiltration of the acini or a differentiation of the acinar
cellsTM. These cancers do not secrete enzymes and their appearance is similar to
human cancers3.
In conclusion tumors developed in rats are essentially of acinar type and those in
hamsters are mostly of ductal type.
3. DIRECT OR INDIRECT HORMONAL SIGNALS IN PANCREATIC
CARCINOGENESIS
The presence of trypsin, chymotrypsin, or bile-pancreatic juice in the rat intestine
suppresses the secretion of exocrine pancreatic enzymes. Conversely, the administ-
ration of trypsin inhibitors (TI) or diversion of bile pancreatic juice from the
duodenum (pancreaticobiliary diversion) result in an increased secretion of diges-
tive enzymes by the pancreas, an enhanced pancreatic response to stimulation by
cholecystokinin (CCK) or caerulein (an amphibian skin polypeptide, structurally
and functionally related to CCK12’13 and pancreatic hypertrophy and
14 16 hyperplasia The trophic effects on the pancreas obtained by chronic injections
of either CCK17 or synthetic caerulein
13 are generally consistent and appear to be
closely associated with increases in DNA, RNA and to[al protein. This suggests144 A. CHRISTOPOULOU ET AL.
that hormonal stimulation, simultaneously enhances hypertrophy and also mitotic
cell division17’18.
Because the administration of exogenous CCK or caerulein stimulates pancreatic
exocrine secretion and also with chronic exposure evokes hypertrophy and hyper-
plasia of the gland 11’19, it is widely held that the stimulatory actions of trypsin
inhibitors or pancreaticobiliary diversion on the pancreas are consistent with
negative feed-back regulation of endogenous CCK concentration. This concept,
originally proposed by Green et al. 2’21 holds that the circulating CCK concentration
is inversely related to the concentration or presence of digestive enzymes (most
notably trypsin or chymotrypsin) in the lumen of the small intestine. Recent direct
experimental evidence for the existence of such an enteral feedback mechanism
involved in regulation of pancreatic secretion and growth, .has come from experi-
ments employing sensitive and relatively specific bioassay and radioimmunoassay
methods and have shown that endogenous circulating CCK levels are elevated in
rats after administration of trypsin inhibitors or pancreaticobiliary diversion2224.
Feeding rats soy flour, containing active trypsin inhibitors results in enlargement
of the pancreas with an increase in synthesis, content and secretion of pancreatic
enzymes25. Similar responses in the rat pancreas are obtained after repeated
injection of CCK17’26. It has been suggested that dietary trypsin inhibitor induces
the chronic release of massive amounts of CCK from the intestinal wall into the
blood stream, and in doing so mediates pancreatic alterations2.
The effects of dietary soybean trypsin inhibitor (SBTI, Kunitz-type) or repeated
injections if 95% pure CCK (CCK-39) on the rat pancreas were investigated in a
10-day experiment. The results indicate that SBTI and CCK-39 mainly exert their
effects on the exocrine pancreas in a similar but not identical manner. These
findings indicate that the intestinal mucosa contains some other unidentified
hormonal factor(s) which exerts atrophic effect on the pancreas and/or potentiates
that induced by CCK. It is suggested, therefore, that SBTI is a potent releaser not
only of CCK but also of another gastrointestinal factor(s) which is associated with
CCK action27.
This view is supported by Kakade et al. 28 who demonstrated that antiproteolytic
activity in raw soy flour is only partially responsible for pancreatic hypertrophy in
the rat. In fact Solomon et al.3 have already shown that secretin markedly increases
the hypertrophic effect of caerulein and modifies the pattern of enzyme changes
seen in response to it. The pancreatic hypertrophy and/or hyperplasia, evoked by
chronic feeding of rats with camostate (FOY-305, a synthetic guanidino-acid ester,
and potent inhibitor of trypsin kallikrein, plasmin, thrombin and phospholipase A2
[29]) or other trypsin inhibitors is believed to be a consequence of elevation of
circulating endogenous CCK concentration, resulting from inhibition of trypsin in
the duodenum224’3. Camostate like other trypsin inhibitors, has been shown
recently to produce hypertrophy or hyperplasia, or both, when administrated
chronically to rats24’31.
It has been shown recently that the administration of CCK receptor antagonists,
proglumide and benzotript fails to fully suppress trypsin inhibitor or pancreaticobi-
liary diversion-induced pancreatic growth in rats22’24. These studies suffer, however,
from the fact that both proglumide and benzotript exhibit only weak in vitro
antagonism or peripheral CCK receptors and also display significant cross-
reactivity for gastrin receptors, which limits their usefulness for in vivo studies32.
Furthermore, Yamagushi et al.
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ration alone results in a slight trophic effect on the rat pancreas in oivo. Goke et
al.24 have also shown that proglumide failed to fully suppress camostate-induced
pancreas growth in rats. These findings suggested that humoral factors in addition
to CCK are involved in enteral regulation of the pancreas in camostate-induced
pancreas growthTM.
For these reasons the role of CCK in camostate-induced pancreas growth was
examined by blocking CCK actions with a specific CCK receptor antagonist
L= 364,71834. This compound, a synthetic benzodiazepine derivative, is a highly
selective peripheral CCK receptor antagonist that exhibits an affinity for these
receptors that is similar to the affinity exhibited by CCK itself34. The observation
that treatment with camostate + L-364,718 failed to significantly suppress pancreas
weights and DNA and RNA concentrations to level below those of control values
does however, suggest the possibility that camostate releases endogenous factors
other than CCK that are weakly trophic for the pancreas and that CCK may play a
role in the maintenance of pancreatic growth in normal rats34.
The effect of tetragastrin (structurally similar to CCK) on pancreatic tumors
induced by azaserine was investigated in wistar rats and it has been shown that
prolonged administration of tetragastrin had little or no influence on the number
and size of the carcinogen induced pancreatic lesions, although it caused signifi-
cantly increased cell proliferation35. Bombesin, another pancreaticotrophic pep-
tide, appear to stimulate the growth of preneoplastic cell lesions in the azaserine-rat
model36.
Recent data indicate that sex hormones may play an important role in pancreatic
carcinogenesis37’38. Effects of sex steroids, on pancreatic carcinogenesis during the
early stages, were studied in azaserine treated rats of both sexes. These results
showed that estradiol treatment and the drop of testosterone levels caused by
castration were highly effective in inhibiting the development and growth of
preneoplastic lesions of the pancreas of the rats treated with azaserine. This
estradiol effect was dose dependent. Therefore, there is evidence that estrogen may
act as an inhibitor and androgen as a promoter in the early stage of pancreatic
carcinogenesis in rats39.
A picture is emerging today of how extracellular signals, including hormones,
can act together with one another, and regulate the intracellular events that
culminate in cell division. Based on operational criteria mitogenic hormones can be
viewed as inducing "competence" or "progression". Both competence and progres-
sion factors are necessary for cell division and to be effective in oitro must be
provided in the correct sequence. If this process is subverted- and clearly there
are many stages at which it could- one likely outcome could be uncontrolled cell
proliferation. Suspicion that such a failure in hormone circuitry may account, at
least in part, for the development of neoplasms has recently been heightened by the
observations from many laboratories that tumor cells can secrete and respond to
their own "growth hormones" thus releasing their dependence on systemic supply
on competence-inducing factors4.
The most popular view today holds that tumor cell growth is regulated by a
combination of endocrinological (systemic), paracrinological (local) and autocrino-
logical (tumor cell derived) hormones.
An imbalance or imbalances in this circuitry, coupled perhaps with the gene-
ration of tumor cells that are hyperresponsive to growth promoting agents, are
sufficient to support uncontrolled cell proliferation. This means that circulating146 A. CHRISTOPOULOU ET AL.
hormones can be expected to explain only one part of the complex system of
carcinogenesis.
4. THE ROLE OF DIET IN EXPERIMENTAL PANCREATIC
CARCINOGENESIS
Dietary influences on carcinogenesis have been shown in various tissues by both
epidemiological and experimental approaches.
Many studies have shown the effects of dietary modification during the post-
initiation phase of pancreatic carcinogenesis.
The nutritional factors that could modify pancreatic carcinogenesis are the
following:
The restriction of calories inhibits carcinogenesis2’5’1.
Proteins
The rats having a diet rich in proteins (50%) have a lower incidence of cancer. In
the contrary diets poor in proteins don’t have this effect5. In hamsters fed on a
low-protein diet, the incidence of pancreatic adenocarcinomas and in situ carcino-
mas was only 13% as compared to 46% in those fed a high protein diet4.
Lipids
The effect of a diet rich in lipids on pancreatic carcinogenesis is variable5’42’43.
Dietary unsaturated fat enhances pancreatic carcinogenesis43. It has been shown
that a diet of 20% unsaturated fat compared to a 20% saturated fat diet or a control
diet (5% unsaturated fat) increased the number of acidophilic acinar loci44.
Trypsin Inhibitors
Research and public attention have been increasingly focussed on the hypothesis
that vitamins and micronutrients may decrease the incidence of some cancers of
epithelial origin such as adenocarcinomas of the pancreas. A few studies have been
reported concerning the possible inhibitory effects of synthetic retinoids on growth
of (pre) neoplastic pancreatic lesions induced in rats and hamsters by carcinogens.
Depending on both the animal model employed and the sex of the animals,
synthetic retinoids have been found to enhance, to inhibit or to have no effect on
45 46 pancreatic carcinogenesis The conflicting nature of these data may be ascribed
to a difference in the types of retinoids used or a difference in the basal diets used,
since in most studies impure (natural ingredients) commercial laboratory diets were
used, which may vary in the amount of (un) saturated fat they contain.
The effects of vitamins A, C and E on pancreatic carcinogenesis were studied in
rats and hamsters maintained on a semipurified diet high in saturated fat (20%) and
it is concluded that vitamins A and C have an inhibitory effect on growth of
acidophilic foci in rats and incidence of early lesions in hamsters. Vitamin E does
not have a potential protective effect on pancreatic carcinogenesis in hamsters47.
Birt et al.
48 found a reduction in pancreatic adenoma incidence by feeding
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of adenomas was observed. They found a consistently elevated incidence of
pancreatic carcinoma in males in another experiment and concluded that retinoids
enhance pancreatic tumor yields in males to a greater extent than in females49.
Longnecker et al. 46’50’51 also demonstrated inhibition of pancreatic carcinogenesis
in the azaserine rat model by a number of retinoids and that selenium enhances this
inhibition.
A great deal of public and scientific controversy was generated by a report
published 10 years ago that coffee consumption could contribute to the develop-
ment of pancreatic cancer53. In a recent comprehensive review, Gordis analyzed 30
epidemiologic studies addressing this relation3. He concluded that although certain
ecologic and case-control studies suggest a possible increase in risk, only a few of
the case-control studies and none of the prospective studies have confirmed a
statistically significant association. On the other hand the effect of chronic coffee
ingestion on dietary fat promoted pancreatic carcinogenesis was investigated in rats
and hamsters, and it is concluded that chronic coffee consumption has an inhibitory
effect on dietary fat promoted carcinogenesis by a mechanism which is still
unknown54.
5. POSSIBLE THERAPEUTIC APPROACH
The possibility of hormonotherapy was recently proposed for pancreatic cancers on
the base of a few clinical studies and experiments55. Experimental studies showed
an antiproliferative effect of somatostatin and its analogues on the growth of
pancreatic cancer. Redding and Schally
56 reported a significant reduction in tumor
weight (51%) and volume (67%) in Wistar Lewis rats bearing the acinar pancreatic
tumor DNCP-322 after 21-days administration of somatostatin analogue, somatos-
tatin 14 (30/g, twice daily). In the second experiment, Syrian golden hamsters
bearing a ductal adenocarcinoma were treated with Somatostatin 14 (20/g, twice
daily) for 30 days with resultant diminished tumor weight and significantly dec-
reased tumor volume compared with controls.
Upp et al.
57 demonstrated inhibition of two human pancreatic cancers (SKI and
CAV) maintained as nude mouse xenografts by the administration of Somastotin
analogue SMS 201-995 (100 /g/kg, IP, three times daily). SKI is a
CCK-receptor-positive tumor whose growth was stimulated by caerulein8 and
CAV is a CCK-receptor-negative tumor whose growth was not stimulated, both
were inhibited to a similar degree by SMS 201-995. Tumor growth of SKI and CAV
was also inhibited when treatment was delayed 21 days after tumor implantation.
The inhibitory effect of Somatostatin on pancreatic cancer may be due partially
to its ability to inhibit the release or action of CCK and secretin. This response
could explain the inhibition seen in CAV, which does not possess CCK receptors
and is not affected by exogenous caerulein58.
Other factors (e.g. EGF) may be important in growth of pancreatic cancer. In
vitro studies demonstrated receptors for Somatostatin and EGF in a cell line from
an undifferentiated human pancreatic cancer (MIA PaCa-2)59. Epidermal growth
factor stimulates in vitro growth of this cancer. Somatostatin reverses the stimula-
tory effect of EGF by activating dephosphorylation of the EGF receptor6. Similar
results have been found on the pancreatic acinar cell line AR-4-21 of the rat61. On
the other hand other investigators, have not found receptors for the Somatostatin148 A. CHRISTOPOULOU ET AL.
on human pancreatic adenocarcinomas biopsies6z. Receptors for sex hormones
have been found in pancreatic tumors that justify the role of hormonotherapy using
antioestrogenes or LHRH analogues in the treatment of pancreatic cancer63.
The effects of Cyclosporine (CsA), an immunosuppressive agent, on azaserine-
induced pancreatic carcinogenesis in rats, were investigated by Longnecker et al.
64
using the short term assays of the quantitation of atypical acinal cell foci. It is
concluded that addition of CsA to the diet inhibits the growth of initiated cells to
form loci in the pancreas of azaserine-treated rats. This experimental model is
useful in analyzing the modifying role of this immunosuppressant in the induction
and growth of epithelial cell tumors, such as adenocarcinoma of the pancreas.
The development of alternative treatments according to biological and biochemi-
cal steps of carcinogenesis is available as adjuvant treatment in order to prevent the
local recurrence or distant metastasis. It may be possible in the future to develop
therapeutic strategies for patients with pancreatic cancer that are based upon
manipulation of the concentrations or effects of hormones and/or dietary elements
in a similar manner to current strategies that are successfully employed in the
treatment of patients with breast cancer.
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